- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04689191
En fase III klinisk studie av gruppe A og C meningokokk polysakkaridvaksine
En randomisert, dobbeltblind, kontrollert, ikke-inferioritetsfase III-studie av en gruppe A og C meningokokkpolysakkaridvaksine hos friske barn i alderen 2-6 år
This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Yunnan
-
Kunming, Yunnan, Kina
- Yunnan Center for Disease Control and Prevention
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
-
The First stage study (An early safety assessment study):
-
18-50 years group:
-
Inclusion Criteria:
- Healthy adults aged 18 to 50 years.
- Proven legal identity.
- Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
- Immunization with any vaccine within 30 days.
- Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
- Any other situations judged by investigators as not suitable for participating in this study.
-
-
7-17 years group:
-
Inclusion Criteria
- Healthy volunteer aged 7 to 17 years.
- Proven legal identity.
- Participants and their legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants and their legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
- Immunization with any vaccine within 30 days.
- Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Women with positive pregnancy test after menarche.
- Any other situations judged by investigators as not suitable for participating in this study.
-
-
2-6 years group:
-
Inclusion Criteria
- Healthy children aged 2 to 6 years.
- Proven legal identity.
- Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
- Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Any other situations judged by investigators as not suitable for participating in this study.
-
The Second stage study (A phase III clinical trial )
-
Inclusion Criteria
- Healthy children aged 2 to 6 years.
- Proven legal identity.
- Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
- Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Any other situations judged by investigators as not suitable for participating in this study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental Vaccine
One dose of Experimental Group A and C meningococcal polysaccharide vaccine |
One dose of Experimental Group A and C meningococcal polysaccharide vaccine |
|
Aktiv komparator: Active Comparator Vaccine
One dose of Control Group A and C meningococcal polysaccharide vaccine |
One dose of Control Group A and C meningococcal polysaccharide vaccine |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Seroconversion rate of Group A meningococcal bactericidal antibody
Tidsramme: 28 days after vaccination
|
Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination |
28 days after vaccination
|
|
Seroconversion rate of Group C meningococcal bactericidal antibody
Tidsramme: 28 days after vaccination
|
Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination |
28 days after vaccination
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse reactions/events rate
Tidsramme: 7 days after vaccination
|
Occurence of adverse reactions/events after vaccination |
7 days after vaccination
|
|
Adverse reactions/events rate
Tidsramme: 28 days after vaccination
|
Occurence of adverse reactions/events after vaccination |
28 days after vaccination
|
|
Serious adverse events
Tidsramme: 6 months after the second vaccination
|
Occurence of Serious adverse events after vaccination |
6 months after the second vaccination
|
|
GMT of Group A meningococcal bactericidal antibody
Tidsramme: 28 days after the second vaccination
|
GMT of Group A meningococcal bactericidal antibody at day 28 after the second vaccination |
28 days after the second vaccination
|
|
GMT of Group C meningococcal bactericidal antibody
Tidsramme: 28 days after the second vaccination
|
GMT of Group C meningococcal bactericidal antibody at day 28 after the second vaccination |
28 days after the second vaccination
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
GMT of IgG antibody against Hepatitis A
Tidsramme: 28 days after the second vaccination
|
GMT of IgG antibody against Hepatitis A at day 28 after vaccination |
28 days after the second vaccination
|
|
Seropositive rate of IgG antibody against Hepatitis A
Tidsramme: 28 days after the second vaccination
|
Seropositive rate of IgG antibody against Hepatitis A at day 28 after vaccination |
28 days after the second vaccination
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Yan Zheng, Mater, Yunnan Center for Disease Control and Prevention
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Nevroinflammatoriske sykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Infeksjoner
- Bakterielle infeksjoner
- Bakterielle infeksjoner og mykoser
- Gram-negative bakterielle infeksjoner
- Infeksjoner i sentralnervesystemet
- Neisseriaceae-infeksjoner
- Meningitt
- Meningitt, bakteriell
- Bakterielle infeksjoner i sentralnervesystemet
- Meningokokkinfeksjoner
- Meningitt, meningokokk
Andre studie-ID-numre
- 20190702
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .